Bilag 4d-WHOb til SOP G00-06-001 - Antimicrobial...
14
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017 TEST FORMS – Introduction Name: Name of laboratory: Name of institute: City: Country: E-mail: Comments: Page 1 of 14 G00-06-001/23.06.2017
Transcript of Bilag 4d-WHOb til SOP G00-06-001 - Antimicrobial...
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017
TEST FORMS – Introduction
Name:
Name of laboratory:
Name of institute:
City:
Country:
E-mail:
Comments:
Page 1 of 11G00-06-001/23.06.2017
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017
TEST FORM – Salmonella Survey on breakpoints applied routinely for antimicrobial susceptibility testing of Salmonella Antimicrobial Interpretation,
Zone diameter (mm) or MIC-value (μg/ml)<, Susceptible Intermediate >, Resistant
Ampicillin, AMP Cefotaxime, CTX Cefoxitin, FOX Ceftazidime, CAZ Ceftriaxone, CRO Chloramphenicol, CHL Ciprofloxacin, CIP Colistin, COL Gentamicin, GEN Meropenem, MER Nalidixic acid, NAL Sulfonamides, SMX Tetracycline, TET Trimethoprim, TMP Trimethoprim + sulfamethoxazole, SXT
Regarding method used for antimicrobial susceptibility testing of Salmonella in this EQAS:
MIC – Microbroth dilution MIC – Macro dilution (tubes) MIC – Agar dilution E-test Disk diffusion Tablets – Neo Sensitabs, Rosco
Brand: Incubation conditions: °C/ h
Regarding antisera used for serotyping of Salmonella in this EQAS:
Brand of antisera:
Comments on which antisera you think is required to complete your serotyping, or other comments:
Page 2 of 11G00-06-001/23.06.2017
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017
TEST FORM – Salmonella
Strain – SalmonellaAntimicrobial
Interpretation
>
Zone diameter (mm) orMIC-value (μg/ml)
S / I / R
WHO S-17.1
_____ _____ Serogroup
_____ _____ Serotype
_____ _____ Antigenic formula
Ampicillin, AMP Cefotaxime, CTX Cefoxitin, FOX Ceftazidime, CAZ Ceftriaxone, CRO Chloramphenicol, CHL Ciprofloxacin, CIP Colistin, COL Gentamicin, GEN Meropenem, MER Nalidixic acid, NAL Sulfonamides, SMX Tetracycline, TET Trimethoprim, TMP Trimethoprim + sulfamethoxazole, SXT
All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.
Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Is the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Indicate the phenotype of the strain: [please select one option]
ESBL-phenotype ESBL+AmpC-phenotype AmpC-phenotype Carbapenemase-phenotype Other phenotype No ESBL, AmpC or carbapenemase
Details from laboratory testingMIC, value or ratio Disks, zone diameter increase
CT
X:C
TX
/Cl
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
CA
Z:C
AZ
/C
l
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
Comments:
TEST FORM – Salmonella Strain – Salmonella Antimicrobial Interpretation
Page 3 of 11G00-06-001/23.06.2017
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017
>
Zone diameter (mm) orMIC-value (μg/ml)
S / I / R
WHO S-17.2
_____ _____ Serogroup
_____ _____ Serotype
_____ _____ Antigenic formula
Ampicillin, AMP Cefotaxime, CTX Cefoxitin, FOX Ceftazidime, CAZ Ceftriaxone, CRO Chloramphenicol, CHL Ciprofloxacin, CIP Colistin, COL Gentamicin, GEN Meropenem, MER Nalidixic acid, NAL Sulfonamides, SMX Tetracycline, TET Trimethoprim, TMP Trimethoprim + sulfamethoxazole, SXT
All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.
Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Is the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Indicate the phenotype of the strain: [please select one option]
ESBL-phenotype ESBL+AmpC-phenotype AmpC-phenotype Carbapenemase-phenotype Other phenotype No ESBL, AmpC or carbapenemase
Details from laboratory testingMIC, value or ratio Disks, zone diameter increase
CT
X:C
TX
/Cl
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
CA
Z:C
AZ
/C
l
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
Comments: TEST FORM – Salmonella
Strain – SalmonellaAntimicrobial
Interpretation
>
Zone diameter (mm) orMIC-value (μg/ml)
S / I / R
Page 4 of 11G00-06-001/23.06.2017
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017
WHO S-17.3
_____ _____ Serogroup
_____ _____ Serotype
_____ _____ Antigenic formula
Ampicillin, AMP Cefotaxime, CTX Cefoxitin, FOX Ceftazidime, CAZ Ceftriaxone, CRO Chloramphenicol, CHL Ciprofloxacin, CIP Colistin, COL Gentamicin, GEN Meropenem, MER Nalidixic acid, NAL Sulfonamides, SMX Tetracycline, TET Trimethoprim, TMP Trimethoprim + sulfamethoxazole, SXT
All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.
Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Is the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Indicate the phenotype of the strain: [please select one option]
ESBL-phenotype ESBL+AmpC-phenotype AmpC-phenotype Carbapenemase-phenotype Other phenotype No ESBL, AmpC or carbapenemase
Details from laboratory testingMIC, value or ratio Disks, zone diameter increase
CT
X:C
TX
/Cl
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
CA
Z:C
AZ
/C
l
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
Comments:
TEST FORM – Salmonella
Strain – SalmonellaAntimicrobial
Interpretation
>
Zone diameter (mm) orMIC-value (μg/ml)
S / I / R
Page 5 of 11G00-06-001/23.06.2017
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017
WHO S-17.4
_____ _____ Serogroup
_____ _____ Serotype
_____ _____ Antigenic formula
Ampicillin, AMP Cefotaxime, CTX Cefoxitin, FOX Ceftazidime, CAZ Ceftriaxone, CRO Chloramphenicol, CHL Ciprofloxacin, CIP Colistin, COL Gentamicin, GEN Meropenem, MER Nalidixic acid, NAL Sulfonamides, SMX Tetracycline, TET Trimethoprim, TMP Trimethoprim + sulfamethoxazole, SXT
All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.
Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Is the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Indicate the phenotype of the strain: [please select one option]
ESBL-phenotype ESBL+AmpC-phenotype AmpC-phenotype Carbapenemase-phenotype Other phenotype No ESBL, AmpC or carbapenemase
Details from laboratory testingMIC, value or ratio Disks, zone diameter increase
CT
X:C
TX
/Cl
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
CA
Z:C
AZ
/C
l
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
Comments:
TEST FORM – Salmonella
Strain – SalmonellaAntimicrobial
Interpretation
>
Zone diameter (mm) orMIC-value (μg/ml)
S / I / R
Page 6 of 11G00-06-001/23.06.2017
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017
WHO S-17.5
_____ _____ Serogroup
_____ _____ Serotype
_____ _____ Antigenic formula
Ampicillin, AMP Cefotaxime, CTX Cefoxitin, FOX Ceftazidime, CAZ Ceftriaxone, CRO Chloramphenicol, CHL Ciprofloxacin, CIP Colistin, COL Gentamicin, GEN Meropenem, MER Nalidixic acid, NAL Sulfonamides, SMX Tetracycline, TET Trimethoprim, TMP Trimethoprim + sulfamethoxazole, SXT
All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.
Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Is the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Indicate the phenotype of the strain: [please select one option]
ESBL-phenotype ESBL+AmpC-phenotype AmpC-phenotype Carbapenemase-phenotype Other phenotype No ESBL, AmpC or carbapenemase
Details from laboratory testingMIC, value or ratio Disks, zone diameter increase
CT
X:C
TX
/Cl
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
CA
Z:C
AZ
/C
l
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
Comments:
TEST FORM – Salmonella
Strain – SalmonellaAntimicrobial
Interpretation
>
Zone diameter (mm) orMIC-value (μg/ml)
S / I / R
Page 7 of 11G00-06-001/23.06.2017
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017
WHO S-17.6
_____ _____ Serogroup
_____ _____ Serotype
_____ _____ Antigenic formula
Ampicillin, AMP Cefotaxime, CTX Cefoxitin, FOX Ceftazidime, CAZ Ceftriaxone, CRO Chloramphenicol, CHL Ciprofloxacin, CIP Colistin, COL Gentamicin, GEN Meropenem, MER Nalidixic acid, NAL Sulfonamides, SMX Tetracycline, TET Trimethoprim, TMP Trimethoprim + sulfamethoxazole, SXT
All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.
Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Is the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Indicate the phenotype of the strain: [please select one option]
ESBL-phenotype ESBL+AmpC-phenotype AmpC-phenotype Carbapenemase-phenotype Other phenotype No ESBL, AmpC or carbapenemase
Details from laboratory testingMIC, value or ratio Disks, zone diameter increase
CT
X:C
TX
/Cl
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
CA
Z:C
AZ
/C
l
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
Comments:
TEST FORM – Salmonella
Strain – SalmonellaAntimicrobial
Interpretation
>
Zone diameter (mm) orMIC-value (μg/ml)
S / I / R
Page 8 of 11G00-06-001/23.06.2017
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017
WHO S-17.7
_____ _____ Serogroup
_____ _____ Serotype
_____ _____ Antigenic formula
Ampicillin, AMP Cefotaxime, CTX Cefoxitin, FOX Ceftazidime, CAZ Ceftriaxone, CRO Chloramphenicol, CHL Ciprofloxacin, CIP Colistin, COL Gentamicin, GEN Meropenem, MER Nalidixic acid, NAL Sulfonamides, SMX Tetracycline, TET Trimethoprim, TMP Trimethoprim + sulfamethoxazole, SXT
All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.
Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Is the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Indicate the phenotype of the strain: [please select one option]
ESBL-phenotype ESBL+AmpC-phenotype AmpC-phenotype Carbapenemase-phenotype Other phenotype No ESBL, AmpC or carbapenemase
Details from laboratory testingMIC, value or ratio Disks, zone diameter increase
CT
X:C
TX
/Cl
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
CA
Z:C
AZ
/C
l
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
Comments:
TEST FORM – Salmonella
Strain – SalmonellaAntimicrobial
Interpretation
>
Zone diameter (mm) orMIC-value (μg/ml)
S / I / R
Page 9 of 11G00-06-001/23.06.2017
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017
WHO S-17.8
_____ _____ Serogroup
_____ _____ Serotype
_____ _____ Antigenic formula
Ampicillin, AMP Cefotaxime, CTX Cefoxitin, FOX Ceftazidime, CAZ Ceftriaxone, CRO Chloramphenicol, CHL Ciprofloxacin, CIP Colistin, COL Gentamicin, GEN Meropenem, MER Nalidixic acid, NAL Sulfonamides, SMX Tetracycline, TET Trimethoprim, TMP Trimethoprim + sulfamethoxazole, SXT
All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.
Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Is the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?
Yes No
Indicate the phenotype of the strain: [please select one option]
ESBL-phenotype ESBL+AmpC-phenotype AmpC-phenotype Carbapenemase-phenotype Other phenotype No ESBL, AmpC or carbapenemase
Details from laboratory testingMIC, value or ratio Disks, zone diameter increase
CT
X:C
TX
/Cl
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
CA
Z:C
AZ
/C
l
MIC ratio 8 (synergy) MIC ratio < 8 Phantom zone (E-test) (synergy) Deformation (E-test) (synergy) Not determinable
Increase 5 mm (synergy) Increase < 5 mm
Comments:
Page 10 of 11G00-06-001/23.06.2017
WHO Collaborating Centre External Quality Assurance System (EQAS) 2017
TEST FORM – E. coli reference strain
Susceptibility testing of E. coli reference strain ATCC 25922
Strain Antimicrobial Zone diameter (mm) orMIC-value (μg/ml)
E. coli ATCC 25922Ampicillin, AMP Cefotaxime, CTX Cefoxitin, FOX Ceftazidime, CAZ Ceftriaxone, CRO Chloramphenicol, CHL Ciprofloxacin, CIP Colistin, COL Gentamicin, GEN Meropenem, MER Nalidixic acid, NAL Sulfamethoxazole, SMX Tetracycline. TET Trimethoprim, TMP Trimethoprim + Sulphonamides , SXT
Page 11 of 11G00-06-001/23.06.2017
